Key facts
- This page summarizes Christopher B. Ehrlich's Form 4 filing for CERO THERAPEUTICS HOLDINGS, INC. (CERO).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 26 Feb 2025, 17:59.
Christopher B. Ehrlich - 24 Feb 2025 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)
- Signature
- /s/ Christopher B. Ehrlich
- Issuer symbol
- CERO
- Transactions as of
- 24 Feb 2025
- Net transaction value
- $0
- Form type
- 4
- Filing time
- 26 Feb 2025, 17:59:49 UTC
- Previous filing
- 04 Dec 2024
- Next filing
- 06 Mar 2025
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
Christopher B. Ehrlich filed Form 4 for CERO THERAPEUTICS HOLDINGS, INC. (CERO) on 26 Feb 2025.
Change
- Previous filing in this sequence was filed on 04 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
CERO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +1,275,000
- Change %
- +100%
- Price
- $0.000000
- Shares after
- 2,550,000
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,275,000
- Exercise price
- $0.1000
- Footnotes
- F1
* indicates a reported price that failed the local validity check.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | On October 1, 2024, the Reporting Person was granted an option to purchase 2,550,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On February 24, 2025, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to the second installment, resulting in the vesting of 1,275,000 shares. |